Fig. 1 · Structure
Documents & Downloads
Conbercept
VEGF Inhibitor
Conbercept is a potent VEGF inhibitor that functions as a soluble receptor decoy, targeting all isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF with high affinity (Kd values of 0.5 pM, 8 pM, and 5 pM, respectively). This recombinant fusion protein, comprising regions from VEGFR-1 and VEGFR-2 fused to the human IgG1 Fc domain, demonstrates significant anti-inflammatory properties, effectively lowering the levels of VEGF, TNF-α, and IL-6, while reducing inflammatory cell infiltration. Conbercept has shown efficacy in decreasing tumor growth in oncology studies and is applicable in treating various ocular diseases, including polypoidal choroidal vasculopathy, diabetic macular edema, and pathologic myopia-related choroidal neovascularization.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 1227158-72-6 |
| Applications | VEGF Inhibitor |
| Molecular Weight | 117.45 kDa |
| Synonyms | KH902 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.